Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.
J Med Chem
; 57(24): 10499-511, 2014 Dec 26.
Article
en En
| MEDLINE
| ID: mdl-25384157
ABSTRACT
Structure-based rational design and extensive structure-activity relationship studies led to the discovery of AMG 232 (1), a potent piperidinone inhibitor of the MDM2-p53 association, which is currently being evaluated in human clinical trials for the treatment of cancer. Further modifications of 1, including replacing the carboxylic acid with a 4-amidobenzoic acid, afforded AM-7209 (25), featuring improved potency (KD from ITC competition was 38 pM, SJSA-1 EdU IC50 = 1.6 nM), remarkable pharmacokinetic properties, and in vivo antitumor activity in both the SJSA-1 osteosarcoma xenograft model (ED50 = 2.6 mg/kg QD) and the HCT-116 colorectal carcinoma xenograft model (ED50 = 10 mg/kg QD). In addition, 25 possesses distinct mechanisms of elimination compared to 1.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Unión Proteica
/
Proteína p53 Supresora de Tumor
/
Neoplasias del Colon
/
Proliferación Celular
/
Proteínas Proto-Oncogénicas c-mdm2
/
Descubrimiento de Drogas
/
Antineoplásicos
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Año:
2014
Tipo del documento:
Article